Art. -Nr.: HY-100869A

MM-589 TFA

Kundenbewertung

Based on 1 Customer Validation

MM-589 TFA is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC₅₀ of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC₅₀ of 12.7 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.67%
CAS. Nr.: 2253167-09-6
Formel: C₃₀H₄₅F₃N₈O₇
Molecular Weight:686.72

Speicherung:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

MM-589 TFA Chemical Structure

CAS. Nr.: 2253167-09-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 0.90 nM (WDR5), 12.7 nM (HMT)^[1]

Ki: <1 nM (WDR5)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HL-60	IC₅₀	8.56 μM Compound: 18; MM-589	Cytotoxicity against human HL60 cells lacking MLL translocation assessed as cell growth inhibition after 4 days by WST8 assay Cytotoxicity against human HL60 cells lacking MLL translocation assessed as cell growth inhibition after 4 days by WST8 assay	[PMID: 28603984]
MOLM-13	IC₅₀	0.1 μM Compound: 18; MM-589	Cytotoxicity against human MOLM13 cells harboring MLL-AF9 fusion protein assessed as cell growth inhibition after 7 days by WST8 assay Cytotoxicity against human MOLM13 cells harboring MLL-AF9 fusion protein assessed as cell growth inhibition after 7 days by WST8 assay	[PMID: 28603984]
MOLM-13	IC₅₀	0.21 μM Compound: 18; MM-589	Cytotoxicity against human MOLM13 cells harboring MLL-AF9 fusion protein assessed as cell growth inhibition after 4 days by WST8 assay Cytotoxicity against human MOLM13 cells harboring MLL-AF9 fusion protein assessed as cell growth inhibition after 4 days by WST8 assay	[PMID: 28603984]
MV4-11	IC₅₀	0.25 μM Compound: 18; MM-589	Cytotoxicity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as cell growth inhibition after 4 days by WST8 assay Cytotoxicity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as cell growth inhibition after 4 days by WST8 assay	[PMID: 28603984]
MV4-11	IC₅₀	0.29 μM Compound: 18; MM-589	Cytotoxicity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as cell growth inhibition after 7 days by WST8 assay Cytotoxicity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as cell growth inhibition after 7 days by WST8 assay	[PMID: 28603984]

In Vitro

MM-589 (0.01-10 μM, 4 days or 7 days) potently and selectively inhibits cell growth in human leukemia cell lines harboring MLL translocations^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

MV4-11 and MOLM-13 cells
Concentration:

0.01, 0.1, 1, 10 μM
Incubation Time:

4 days or 7 days
Result:

Potently inhibited MV4-11 and MOLM-13 cell growth with IC₅₀s of 0.25 and 0.21 μM, respectively. Had much weaker activity in the inhibition of cell growth of the HL-60 cell line with an IC₅₀ of 8.6 μM.

Chemical Information

CAS. Nr. 2253167-09-6
Appearance Solid
Molecular Weight 686.72
Formel C₃₀H₄₅F₃N₈O₇
Color White to off-white
SMILES

O=C(NCC[C@](NC(C(C)C)=O)(C)C1=O)[C@H](NC([C@@H](NC([C@H](CCCNC(NC)=N)N1)=O)CC)=O)C2=CC=CC=C2.FC(C(O)=O)(F)F
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (145.62 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4562 mL

7.2810 mL

14.5620 mL

5 mM

0.2912 mL

1.4562 mL

2.9124 mL

10 mM

0.1456 mL

0.7281 mL

1.4562 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Karatas H, et al. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction. J Med Chem. 2017 Jun 22;60(12):4818-4839. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4562 mL	7.2810 mL	14.5620 mL	36.4049 mL
	5 mM	0.2912 mL	1.4562 mL	2.9124 mL	7.2810 mL
	10 mM	0.1456 mL	0.7281 mL	1.4562 mL	3.6405 mL
	15 mM	0.0971 mL	0.4854 mL	0.9708 mL	2.4270 mL
	20 mM	0.0728 mL	0.3640 mL	0.7281 mL	1.8202 mL
	25 mM	0.0582 mL	0.2912 mL	0.5825 mL	1.4562 mL
	30 mM	0.0485 mL	0.2427 mL	0.4854 mL	1.2135 mL
	40 mM	0.0364 mL	0.1820 mL	0.3640 mL	0.9101 mL
	50 mM	0.0291 mL	0.1456 mL	0.2912 mL	0.7281 mL
	60 mM	0.0243 mL	0.1213 mL	0.2427 mL	0.6067 mL
	80 mM	0.0182 mL	0.0910 mL	0.1820 mL	0.4551 mL
	100 mM	0.0146 mL	0.0728 mL	0.1456 mL	0.3640 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MM-589 TFA

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MM-589 TFA

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MM-589 TFA Related Classifications

HY-100869A Related Classifications